TIAA CREF Investment Management’s Viridian Therapeutics VRDN Stock Holding History

TIAA CREF Investment Management’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$272K	Buy	6,510 +1,068	+20%	+$48.3K	﹤0.01%	2809
2018 Q4	$247K	Sell	5,442 -86	-2%	-$4.97K	﹤0.01%	2826
2018 Q3	$463K	Sell	5,528 -613	-10%	-$57.8K	﹤0.01%	2748
2018 Q2	$590K	Buy	6,141 +1,905	+45%	+$201K	﹤0.01%	2713
2018 Q1	$445K	Buy	4,236 +1,709	+68%	+$186K	﹤0.01%	2790
2017 Q4	$395K	Buy	2,527 +107	+4%	+$13.6K	﹤0.01%	2875
2017 Q3	$332K	Buy	2,420 +76	+3%	+$12.8K	﹤0.01%	2978
2017 Q2	$455K	Buy	+2,344	New	+$396K	﹤0.01%	2903

Other funds holding VRDN

AVA

Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TIAA CREF Investment Management's VRDN Position: Q1 2019 in Review

TIAA CREF Investment Management increased its Viridian Therapeutics (VRDN) stake by 20% in Q1 2019, buying an estimated $48.3K and bringing the position to 6,510 shares worth $272K. The position accounts for ﹤0.01% of the portfolio, ranked #2809.

TIAA CREF Investment Management first reported a position in VRDN in Q2 2017 and has held it in 8 quarters since. The position peaked at $590K in Q2 2018. 51 funds tracked by Wall St. Rank hold VRDN as of Q1 2019.

TIAA CREF Investment Management held 6,510 shares of Viridian Therapeutics worth $272K as of Q1 2019.
TIAA CREF Investment Management bought 1,068 Viridian Therapeutics shares in Q1 2019, an estimated $48.3K.
Viridian Therapeutics made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2809 holding.
TIAA CREF Investment Management first reported a position in Viridian Therapeutics in Q2 2017 and has held it in 8 quarters since.
TIAA CREF Investment Management's Viridian Therapeutics position peaked at $590K in Q2 2018.
51 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.